In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Coherus Biosciences Inc (NASDAQ: CHRS) closed the day trading at $2.08 down -0.48% from the previous closing price of $2.09. In other words, the price has decreased by -$0.48 from its previous closing price. On the day, 2.2 million shares were traded. CHRS stock price reached its highest trading level at $2.1951 during the session, while it also had its lowest trading level at $2.0.
Ratios:
For a better understanding of CHRS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.05 and its Current Ratio is at 1.17.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on November 17, 2023, initiated with a Outperform rating and assigned the stock a target price of $11.
On July 24, 2023, Citigroup started tracking the stock assigning a Buy rating and target price of $12.Citigroup initiated its Buy rating on July 24, 2023, with a $12 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 22 ’23 when Lanfear Dennis M sold 223,100 shares for $2.02 per share. The transaction valued at 449,770 led to the insider holds 731,693 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CHRS now has a Market Capitalization of 239776144 and an Enterprise Value of 460017536. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.79. Its current Enterprise Value per Revenue stands at 1.524 whereas that against EBITDA is -2.937.
Stock Price History:
Over the past 52 weeks, CHRS has reached a high of $5.63, while it has fallen to a 52-week low of $1.43. The 50-Day Moving Average of the stock is -7.20%, while the 200-Day Moving Average is calculated to be -30.36%.
Shares Statistics:
Over the past 3-months, CHRS traded about 2.28M shares per day on average, while over the past 10 days, CHRS traded about 2038890 shares per day. A total of 114.73M shares are outstanding, with a floating share count of 112.50M. Insiders hold about 1.94% of the company’s shares, while institutions hold 76.04% stake in the company. Shares short for CHRS as of 1714435200 were 21687633 with a Short Ratio of 9.50, compared to 1711584000 on 23447884. Therefore, it implies a Short% of Shares Outstanding of 21687633 and a Short% of Float of 22.35.
Earnings Estimates
The dynamic stock of Coherus Biosciences Inc (CHRS) is currently being evaluated by a team of 4.0 analysts, each contributing to its current rating.On average, analysts expect EPS of -$0.26 for the current quarter, with a high estimate of -$0.23 and a low estimate of -$0.33, while EPS last year was -$0.38. The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.11 and low estimates of -$0.21.
Analysts are recommending an EPS of between -$0.41 and -$0.96 for the fiscal current year, implying an average EPS of -$0.75. EPS for the following year is -$0.11, with 4.0 analysts recommending between $0.5 and -$0.57.
Revenue Estimates
For the next quarter, 5 analysts are estimating revenue of $59.52M. There is a high estimate of $65M for the next quarter, whereas the lowest estimate is $55M.
A total of 8 analysts have provided revenue estimates for CHRS’s current fiscal year. The highest revenue estimate was $411M, while the lowest revenue estimate was $246.33M, resulting in an average revenue estimate of $278.78M. In the same quarter a year ago, actual revenue was $257.24MBased on 8 analysts’ estimates, the company’s revenue will be $365.54M in the next fiscal year. The high estimate is $513.75M and the low estimate is $279.91M.
